Grimes & Company, Inc. Immunity Bio, Inc. Transaction History
Grimes & Company, Inc.
- $3.58 Billion
- Q2 2025
A detailed history of Grimes & Company, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 58,436 shares of IBRX stock, worth $175,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,436
Previous 10,000
484.36%
Holding current value
$175,892
Previous $30,000
413.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IBRX
# of Institutions
246Shares Held
80.5MCall Options Held
1.09MPut Options Held
2.73M-
Vanguard Group Inc Valley Forge, PA20.3MShares$61.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$34.4 Million0.0% of portfolio
-
State Street Corp Boston, MA7.58MShares$22.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.29MShares$12.9 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.45MShares$10.4 Million0.07% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.2B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...